ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Mouse Models, Other"

  • Abstract Number: 0727 • ACR Convergence 2023

    A Novel Active Pemphigus Vulgaris Mouse Model Induced by Immunization with TLR Ligand Adjuvanted Recombinant Desmoglein 3 Protein Vaccine

    Changxing Gao, Zijun Wang and Qianjin Lu, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China; Key Laboratory of Basic and Translational Research on Immune-Mediated Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, China. 3. Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China

    Background/Purpose: Pemphigus vulgaris (PV) is an autoimmune bullous skin disease mediated by desmoglein-3 (Dsg3) specific auto-antibody present in skin and mucosae. The binding of pathogenic…
  • Abstract Number: 0803 • ACR Convergence 2023

    IL10 Inhibits Toll-like Receptor-9-induced T Cell Receptor-mediated T Cell Activation in Macrophage Activation Syndrome

    Matthew Eremita1, Omar Geier2, Joyce Hui-Yuen1 and Matthew Taylor3, 1Division of Pediatric Rheumatology, Cohen Children's Medical Center, Lake Success, NY, 2Sepsis Research Laboratory, Feinstein Institutes for Medical Research, Manhasset, NY, 3Division of Pediatric Critical Care, Cohen Children's Medical Center, Manhasset, NY

    Background/Purpose: Macrophage activation syndrome (MAS) is a potentially fatal complication of systemic juvenile idiopathic arthritis (sJIA). Gene expression pathway analyses have identified altered Toll-like receptor…
  • Abstract Number: 0870 • ACR Convergence 2023

    Targeting Peroxisome Proliferator-Activated Receptor α Is a Disease-Modifying Therapy for Osteoarthritis

    Uxía nogueira Recalde1, Patricia Díaz rodríguez2, Francisco J. Blanco3, Eduardo Dominguez Medina4 and Beatriz Carames5, 1Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomedica de A Coruña (iNIBIC), A Coruña, Spain, 2Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Pharmacy School, Santiago de Compostela, Spain, 3Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, 4Center for Research in Molecular Medicine and Chronic Diseases, Santiago de Compostela, Spain, 5Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain

    Background/Purpose: Disease-modifying therapeutic agents to prevent progression of Osteoarthritis (OA) are an urgent clinical need. Targeting senescence and autophagy in chondrocytes with small molecules is…
  • Abstract Number: 0880 • ACR Convergence 2023

    CD14 Inhibition as a Potential Therapeutic in Post Traumatic OA

    Kevin Burt1, Vu Nguyen1, Lance Murphy2, De'Broski Herbert1, Robert Mauck1 and Carla Scanzello3, 1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 3Translational Musculoskeletal Research Center, Corp. Michael J Crescenz VA Medical Center,4Division of Rheumatology, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Osteoarthritis (OA) is the most common joint disorder, and growing evidence has identified inflammation to be a major driver of disease progression. During disease,…
  • Abstract Number: 1591 • ACR Convergence 2023

    Complement Factor D/Adipsin Knockout Mice Demonstrate Disparate Pain and Structural Damage Phenotypes in Obesity-induced Post Traumatic Osteoarthritis

    Kelsey Collins1, Kristin Lenz2, Arin Oestreich2, Luke Springer2, Antonina Akk2, Huimin Yan2, Xiaobo Wu2, John Atkinson3, Christine Pham4 and Farshid Guilak4, 1University of California San Francisco, San Francisco, CA, 2Washington University in St. Louis, St. Louis, MO, 3Washington University School of Medicine, St. Louis, MO, 4Washington University, St. Louis, MO

    Background/Purpose: Osteoarthritis (OA) is the leading cause of musculoskeletal pain, which is a primary driver of care-seeking behavior. There is lack of mechanistic information detailing…
  • Abstract Number: 079 • 2023 Pediatric Rheumatology Symposium

    Dynamics of Neutrophil Activation in Repeated TLR-9-Induced Mouse Model of Macrophage Activation Syndrome

    Natsumi Inoue, Richard Chhaing, Sanjeev Dhakal, Thuy Do and Grant Schulert, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening complication of rheumatic diseases including systemic juvenile idiopathic arthritis (SJIA). SJIA shows prominent neutrophil activation with expansion…
  • Abstract Number: L10 • ACR Convergence 2022

    Efgartigimod Prevents Necrosis and Allows for Muscle Fiber Regeneration in a Humanized Mouse Model of Immune-mediated Necrotizing Myopathy (IMNM)

    Sarah Julien1, Emma Briand1, Bas van der Woning2, Leentje de ceuninck3, Rachid zoubari1, olivier benveniste4, laurent drouot1 and olivier boyer5, 1INSERM U1234, PAn’THER FOCIS Center of Excellence, Rouen, France, 2argenx, Boston, MA, 3argenx, Ghent, Belgium, 4AP-HP, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Paris, France, 5INSERM U1234, PAn’THER FOCIS Center of Excellence; Rouen University Hospital, Department of Immunology and Biotherapy, Rouen, France

    Background/Purpose: Immune-mediated necrotizing myopathy (IMNM) is a severe form of myositis characterized by muscle weakness and elevated creatine kinase levels in serum. The most frequent…
  • Abstract Number: 1622 • ACR Convergence 2022

    TNF Receptor 1 Drives Murine Pulmonary Arterial Hypertension and Is Characterized by Loss of Capillary Endothelial Cells and Pericytes, Smooth Muscle Cell Proliferation, and Alterations in Fibroblast Phenotype

    Stacey Duemmel1, Marc Nuzzo1, Soumyaroop Bhattacharya1, Qingfu Xu1, Amy Mohan1 and Benjamin Korman2, 1URMC, Rochester, NY, 2University of Rochester, Rochester, NY

    Background/Purpose: We previously demonstrated that TNF-transgenic (TNF-Tg) mice have findings consistent with connective-tissue disease associated pulmonary arterial hypertension (CTD-PAH), and that this pathology is mediated…
  • Abstract Number: 1708 • ACR Convergence 2022

    A Role for the RAGE Receptor in Chronic Neurotoxicity After Exposure to SLE Antibodies That Cross React with dsDNA and the NMDA Receptor

    Bahtiyar Toz1, Jeffrey C wingard2, Bruce Volpe2 and Betty Diamond2, 1Resident in Queens Hospital Center, Jamaica, NY, 2Feinstein Institutes for Medical Research, Manhasset, NY

    Background/Purpose: Neurologic dysfunction occurs in up to 80% of SLE patients. Cognitive impairment is one of the most frequent manifestations of neuropsychiatric SLE (NPSLE). There…
  • Abstract Number: 1732 • ACR Convergence 2022

    Novel Human Class II MHC Tetramers Detect Rare, Self-Reactive CD4+ T Cells Relevant to Mixed Connective Tissue Disease

    Shawn Mahmud, Thamotharampillai Dileepan, Bryce Binstadt and Marc Jenkins, University of Minnesota, Minneapolis, MN

    Background/Purpose: Nearly all patients with mixed connective tissue disease (MCTD) have IgG autoantibodies (autoAb) specific for U170k, a component of the U1-snNRP spliceosomal complex. A…
  • Abstract Number: 1741 • ACR Convergence 2022

    Mutated Nod2 Controls T Cell Function and Promotes Uveitis in a Blau Syndrome Mouse Model

    Leah Huey1, Kylie Koney1, Emily Vance1, Chia-Feng Tsai2, Rosalie K. Chu2, Marina A. Gritsenko2, Ellen Lee1, Holly Rosenzweig1 and Ruth Napier1, 1Oregon Health & Science University and VA Portland Health Care System, Portland, OR, 2Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA

    Background/Purpose: Mutations in the microbial signaling molecule NOD2 cause granulomatous uveitis, arthritis, and dermatitis in Blau Syndrome. We previously showed a novel role for Nod2…
  • Abstract Number: 1883 • ACR Convergence 2022

    Auto-antibodies Targeting Membrane Repair Proteins Enhances Myositis Phenotype

    Shane Bruckner1, Kassidy Banford2, hannah Bulgart2, Kevin mcElhanon3, Rohit Aggarwal4, Chester Oddis5, Noah Weisleder1 and Wael Jarjour1, 1The Ohio State University, Columbus, OH, 2The Ohio State University Wexner Medical Center, Columbus, OH, 3Pfizer Inc., Cambridge, MA, 4Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 5University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of disorders in which autoimmune responses produce a chronic state of inflammation resulting in degeneration of skeletal…
  • Abstract Number: 2021 • ACR Convergence 2022

    Early Histopathological Changes of the Salivary Glands Associated with the Development of Primary Sjögren’s Syndrome

    Xiaomei Shan1, Clara Reichardt1, Jeeshan Singh1, Anne Zeitler2, Christine Schauer1, Jasmin Knopf1, Martin Herrmann1, Gerhard Grossmayer1, Georg Schett1 and Luis Munoz1, 1Universitätsklinikum Erlangen, Erlangen, Germany, 2Friedrich-Alexander University Erlangen Nürnberg, Erlangen, Germany

    Background/Purpose: Primary Sjögren's syndrome (PSS) is a chronic inflammatory disease affecting exocrine glands including salivary and lacrimal glands that leads to dry eyes and mouth…
  • Abstract Number: 2263 • ACR Convergence 2022

    Nanotherapeutic Approaches for the Treatment of Post-traumatic Osteoarthritis

    Luke Springer1, Kelsey Collins2, Huimin Yan2, Ying Hu3, Farshid Guilak2, Samuel Wickline4, Hua Pan2 and Christine Pham2, 1Washington University School of Medicine, St. Louis, MO, 2Washington University School of Medicine, Saint Louis, MO, 3Washington University, Saint Louis, MO, 4University of South Florida, Tampa, FL

    Background/Purpose: Osteoarthritis (OA) represents the most common form of arthritis and is a major cause of morbidity in the aging population. Post-traumatic OA (PTOA) is…
  • Abstract Number: 0004 • ACR Convergence 2022

    mTORC1 Drives the Spectrum of Pathology in Systemic JIA and Macrophage Activation Syndrome

    zhengping huang1, xiaomeng You2, Liang Chen3, Yan Du3, Kailey Brodeur3, Qiang Wang3, David Sykes4, Margaret Chang5, Julia Charles2, Peter Nigrovic5 and Pui Lee5, 1Guangdong Second Provincial Hospital, Guangzhou, China, 2Brigham and Women's Hospital, Boston, MA, 3Boston Children's Hospital, Boston, MA, 4Massachusetts General Hospital, Boston, MA, 5Division of Immunology, Boston Children's Hospital, Boston, MA

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a severe inflammatory syndrome characterized by fever, skin rash and arthritis. A subset of patients with sJIA develop…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology